← All trials
NCT03431428
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2018
- Primary completion
- Jan 1, 2020
- Completion date
- Dec 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 477
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dalian Medical UniversityLead sponsor
- Dalian Medical UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Harbin Medical UniversityOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
- Jilin Provincial Tumor HospitalOverall official - principal investigator
- Dalian Medical UniversityStudy director
- Dalian Medical UniversitySponsor investigator
- Shengjing HospitalOverall official - principal investigator
- The First People's Hospital of JingzhouOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.